Creative Medical Technology Holdings, Inc. Liabilities, Fair Value Adjustment
Creative Medical Technology Holdings, Inc. (CELZ) reported Liabilities, Fair Value Adjustment of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2023-03-31
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for the quarter ending 2022-12-31 was $0.00.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for the quarter ending 2021-12-31 was $0.00.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for the quarter ending 2020-03-31 was $4.40M, a 1559.61% increase year-over-year.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for the quarter ending 2019-12-31 was -$4.43M, a 262.84% decline year-over-year.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for fiscal 2021 was $26.03M.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for fiscal 2019 was -$5.09M.
- Creative Medical Technology Holdings, Inc. liabilities, fair value adjustment for fiscal 2018 was -$11.59M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $26.03M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $26.03M 10-Q · filed 2022-11-10 | |||
| 2020-03-31 | $4.40M 10-Q · filed 2020-05-15 | -$33.43K derived: sum of 2 quarters · filed 2020-05-15 | -$1.65M derived: sum of 3 quarters · filed 2020-05-15 | -$956.36K derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | -$4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | -$6.05M derived: sum of 2 quarters · filed 2020-04-06 | -$5.36M derived: sum of 3 quarters · filed 2020-04-06 | -$5.09M 10-K · filed 2020-04-06 |
| 2019-09-30 | -$1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$922.93K derived: sum of 2 quarters · filed 2019-11-14 | -$657.76K 10-Q · filed 2019-11-14 | $2.07M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-06-30 | $691.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $956.65K 10-Q · filed 2019-08-13 | $3.68M derived: sum of 3 quarters · filed 2020-05-15 | $2.76M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-03-31 | $265.17K 10-Q · filed 2020-05-15 | $2.99M derived: sum of 2 quarters · filed 2020-05-15 | $2.07M derived: sum of 3 quarters · filed 2020-05-15 | -$4.29M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $1.80M derived: sum of 2 quarters · filed 2020-04-06 | -$4.55M derived: sum of 3 quarters · filed 2020-04-06 | -$11.59M 10-K · filed 2020-04-06 |
| 2018-09-30 | -$919.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$7.27M derived: sum of 2 quarters · filed 2019-11-14 | -$14.31M 10-Q · filed 2019-11-14 | -$15.36M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$13.39M 10-Q · filed 2019-08-13 | -$14.44M derived: sum of 3 quarters · filed 2019-08-13 | -$14.07M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | -$7.04M 10-Q · filed 2019-05-20 | -$8.09M derived: sum of 2 quarters · filed 2019-05-20 | -$7.71M derived: sum of 3 quarters · filed 2019-05-20 | -$8.14M derived: sum of 4 quarters · filed 2019-05-20 |
| 2017-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$676.59K derived: sum of 2 quarters · filed 2019-04-01 | -$1.10M derived: sum of 3 quarters · filed 2019-04-01 | -$1.10M 10-K · filed 2019-04-01 |
| 2017-09-30 | $372.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$54.53K derived: sum of 2 quarters · filed 2018-11-14 | -$54.53K 10-Q · filed 2018-11-14 | -$54.53K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | -$427.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$427.13K 10-Q · filed 2018-08-14 | -$427.13K derived: sum of 3 quarters · filed 2018-08-14 | -$427.13K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $0.00 10-Q · filed 2018-08-03 | $0.00 derived: sum of 2 quarters · filed 2018-08-03 | $0.00 derived: sum of 3 quarters · filed 2018-08-03 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 derived: sum of 2 quarters · filed 2018-03-29 | $0.00 10-K · filed 2018-03-29 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $0.00 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |